Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2

Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2

Repurposing studies have identified several FDA-approved compounds as potential inhibitors of the intracellular domain of epidermal growth factor receptor 1 (EGFR) and human epidermal receptor 2 (HER2). EGFR and HER2 represent important targets for the design of new drugs against different types of...

Full description

Bibliographic Details
Main Authors: Irving Balbuena-Rebolledo, Itzia Irene Padilla-Martínez, Martha Cecilia Rosales-Hernández, Martiniano Bello
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Pharmaceuticals
Subjects:
HER2
EGFR
doxazosin
docking
MD simulations
Online Access:https://www.mdpi.com/1424-8247/14/8/791

Similar Items

Similar Items